Propanc Biopharma, Inc. Common Stock Total Liabilities
Propanc Biopharma, Inc. Common Stock total liabilities. Based on the latest financial reports, Propanc Biopharma, Inc. Common Stock (PPCB) has total liabilities worth $3.38 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See PPCB defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Propanc Biopharma, Inc. Common Stock (2010–2026)
Total liabilities of Propanc Biopharma, Inc. Common Stock from 2010 to 2026. This chart illustrates how Propanc Biopharma, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Propanc Biopharma, Inc. Common Stock to see how much of total assets are deployed in long-term investments.
Propanc Biopharma, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Propanc Biopharma, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Helium Inc
V:HELI
|
Canada | CA$4.02 Million |
|
Traws Pharma Inc
NASDAQ:TRAW
|
USA | $9.78 Million |
|
Ducon Infratechnologies Limited
NSE:DUCON
|
India | Rs1.39 Billion |
|
Belmont Resources Inc
V:BEA
|
Canada | CA$113.78K |
|
STREAMPLAY STUDIO LTD.
F:GIX0
|
Germany | €1.45 Million |
|
HELIX Resources Ltd
AU:HLX
|
Australia | AU$753.28K |
|
Bindi Metals Ltd
AU:BIM
|
Australia | AU$138.04K |
|
Evolution Energy Minerals Ltd
AU:EV1
|
Australia | AU$257.93K |
Liability Composition Analysis (2010–2026)
This chart breaks down Propanc Biopharma, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Propanc Biopharma, Inc. Common Stock.
Liquidity & Leverage Metrics
Propanc Biopharma, Inc. Common Stock Total Liabilities Ratios Explained
Propanc Biopharma, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Propanc Biopharma, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Propanc Biopharma, Inc. Common Stock (2010–2026)
The table below shows the annual total liabilities of Propanc Biopharma, Inc. Common Stock from 2010 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | $3.38 Million | -41.00% |
| 2025-06-30 | $5.73 Million | +48.66% |
| 2024-06-30 | $3.85 Million | +21.21% |
| 2023-06-30 | $3.18 Million | +2.33% |
| 2022-06-30 | $3.11 Million | +0.80% |
| 2021-06-30 | $3.08 Million | -17.63% |
| 2020-06-30 | $3.74 Million | -15.06% |
| 2019-06-30 | $4.40 Million | -35.47% |
| 2018-06-30 | $6.82 Million | +23.24% |
| 2017-06-30 | $5.54 Million | +88.04% |
| 2016-06-30 | $2.94 Million | -20.00% |
| 2015-06-30 | $3.68 Million | +141.82% |
| 2014-06-30 | $1.52 Million | +91.64% |
| 2013-06-30 | $794.22K | +35.95% |
| 2012-06-30 | $584.19K | +90.38% |
| 2011-06-30 | $306.85K | +32.97% |
| 2010-06-30 | $230.76K | -- |
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. Th… Read more